162 related articles for article (PubMed ID: 31092511)
1. Switching immunoglobulin products, what are the implications? Result of 2018 census of immunology centres.
Bethune C; Herriot R
Clin Med (Lond); 2019 May; 19(3):201-204. PubMed ID: 31092511
[TBL] [Abstract][Full Text] [Related]
2. The Nuts and Bolts of Immunoglobulin Treatment for Antibody Deficiency.
Wasserman RL
J Allergy Clin Immunol Pract; 2016; 4(6):1076-1081.e3. PubMed ID: 27836057
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of 16% subcutaneous immunoglobulin compared with 20% subcutaneous immunoglobulin in primary antibody deficiency.
Niebur HB; Duff CM; Shear GF; Nguyen D; Alberdi TK; Dorsey MJ; Sleasman JW
Clin Exp Immunol; 2015 Sep; 181(3):441-50. PubMed ID: 25761372
[TBL] [Abstract][Full Text] [Related]
4. Immunoglobulin Replacement Therapy for Primary Immunodeficiency.
Sriaroon P; Ballow M
Immunol Allergy Clin North Am; 2015 Nov; 35(4):713-30. PubMed ID: 26454315
[TBL] [Abstract][Full Text] [Related]
5. Immunoglobulin replacement therapy for primary immunodeficiencies.
Peter JG; Chapel H
Immunotherapy; 2014; 6(7):853-69. PubMed ID: 25290417
[TBL] [Abstract][Full Text] [Related]
6. Immunoglobulin treatment in primary antibody deficiency.
Maarschalk-Ellerbroek LJ; Hoepelman IM; Ellerbroek PM
Int J Antimicrob Agents; 2011 May; 37(5):396-404. PubMed ID: 21276714
[TBL] [Abstract][Full Text] [Related]
7. [Prevention and therapy with immunoglobulin SRK].
Schnoz M; Ryser DH; Barandun S; Eckmann L
Helv Chir Acta; 1979 May; 46(1-2):111-3. PubMed ID: 38227
[TBL] [Abstract][Full Text] [Related]
8. Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies.
Canessa C; Iacopelli J; Pecoraro A; Spadaro G; Matucci A; Milito C; Vultaggio A; Agostini C; Cinetto F; Danieli MG; Gambini S; Marasco C; Trizzino A; Vacca A; De Mattia D; Martire B; Plebani A; Di Gioacchino M; Gatta A; Finocchi A; Licciardi F; Martino S; De Carli M; Moschese V; Azzari C
Int J Immunopathol Pharmacol; 2017 Mar; 30(1):73-82. PubMed ID: 27927705
[TBL] [Abstract][Full Text] [Related]
9. 20% subcutaneous immunoglobulin for patients with primary immunodeficiency diseases: A systematic review.
Song J; Zhang L; Li Y; Quan S; Liang Y; Zeng L; Liu Y
Int Immunopharmacol; 2015 Apr; 25(2):457-64. PubMed ID: 25633961
[TBL] [Abstract][Full Text] [Related]
10. Pharmacoeconomics of immunoglobulins in primary immunodeficiency.
Simoens S
Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):375-86. PubMed ID: 19670998
[TBL] [Abstract][Full Text] [Related]
11. Immunoglobulin use in immune deficiency in the UK: a report of the UKPID and National Immunoglobulin Databases.
Shillitoe B; Hollingsworth R; Foster M; Garcez T; Guzman D; Edgar JD; Buckland M
Clin Med (Lond); 2018 Oct; 18(5):364-370. PubMed ID: 30287427
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases.
Ochs HD; Gupta S; Kiessling P; Nicolay U; Berger M;
J Clin Immunol; 2006 May; 26(3):265-73. PubMed ID: 16783465
[TBL] [Abstract][Full Text] [Related]
13. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy.
Chapel HM; Spickett GP; Ericson D; Engl W; Eibl MM; Bjorkander J
J Clin Immunol; 2000 Mar; 20(2):94-100. PubMed ID: 10821460
[TBL] [Abstract][Full Text] [Related]
14. Managing patients with side effects and adverse events to immunoglobulin therapy.
Azizi G; Abolhassani H; Asgardoon MH; Shaghaghi S; Negahdari B; Mohammadi J; Rezaei N; Aghamohammadi A
Expert Rev Clin Pharmacol; 2016; 9(1):91-102. PubMed ID: 26496172
[TBL] [Abstract][Full Text] [Related]
15. Rapid Push vs Pump-Infused Subcutaneous Immunoglobulin Treatment: a Randomized Crossover Study of Quality of Life in Primary Immunodeficiency Patients.
Bienvenu B; Cozon G; Mataix Y; Lachaud D; Alix A; Hoarau C; Antier D; Hachulla E; Brice S; Viallard JF; Tamisier S; Fauchais AL; Renon-Carron F; Clerson P; Fardini Y; Crave JC; Miossec P
J Clin Immunol; 2018 May; 38(4):503-512. PubMed ID: 29855752
[TBL] [Abstract][Full Text] [Related]
16. [Therapeutic use of immunoglobulins in children (author's transl)].
Hitzig WH
Blut; 1980 Mar; 40(3):215-24. PubMed ID: 6988023
[TBL] [Abstract][Full Text] [Related]
17. [Clinical results with a new intravenous immunoglobulin preparation (author's transl)].
Hansi W; Kratzsch G; Heimpel H
Dtsch Med Wochenschr; 1980 Nov; 105(48):1675-80. PubMed ID: 7439053
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of home-based subcutaneous immunoglobulin replacement therapy in paediatric patients with primary immunodeficiencies.
Borte M; Bernatowska E; Ochs HD; Roifman CM;
Clin Exp Immunol; 2011 Jun; 164(3):357-64. PubMed ID: 21413943
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous immunoglobulins replacement therapy in secondary antibody deficiencies: Real life evidence as compared to primary antibody deficiencies.
Cinetto F; Neri R; Vianello F; Visentin A; Barilà G; Gianese S; Lanciarotta A; Milito C; Rattazzi M; Piazza F; Trentin L; Zambello R; Agostini C; Scarpa R
PLoS One; 2021; 16(3):e0247717. PubMed ID: 33661940
[TBL] [Abstract][Full Text] [Related]
20. Evaluating dose ratio of subcutaneous to intravenous immunoglobulin therapy among patients with primary immunodeficiency disease switching to 20% subcutaneous immunoglobulin therapy.
Krishnarajah G; Lehmann JK; Ellman B; Bhak RH; DerSarkissian M; Leader D; Bullinger AL; Sheng Duh M
Am J Manag Care; 2016 Oct; 22(15 Suppl):s475-s481. PubMed ID: 27849353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
